[Antiandrogen in prostate cancer].
Maeda
Osamu
O
Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
Usami
Michiyuki
M
D000726:Androgen Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000813:Anilides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D011944:Receptors, Androgen / Q000378:metabolism; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D011944:Receptors, Androgen; D014105:Tosyl Compounds; D005485:Flutamide; C053541:bicalutamide